ARTICLE | Company News

Auxilium endocrine/metabolic, genitourinary, musculoskeletal news

October 6, 2014 7:00 AM UTC

Auxilium will reduce headcount by about 30% to consolidate commercial operations and will focus on near-term R&D milestones. Auxilium said it had 639 employees at the end of 2013, but declined to disclose detail of the cuts, including departments and locations. The company expects to reduce annual operating expenses by at least $75 million.

Auxilium will realign and consolidate its three sales forces into two sales forces, with a single urology-focused sales force. Auxilium said the consolidated operations will strengthen its urology and men's healthcare franchises, including Xiaflex collagenase clostridium histolyticum for Peyronie's disease; Testopel, a long-acting implantable testosterone replacement therapy; and erectile dysfunction drugs Edex alprostadil and Stendra avanafil. The company said it will also maintain targeted commercial resources to continue growth of Xiaflex for Dupuytren's contracture. ...